<p>(A) In luminal epithelial cell-lines (e.g. in HMLE, HMLER, MCF7) the conventional model describes breast CSCs as M cells and ‘non cancer stem cells’ as E cells. Paradoxically, in more basal mesenchymal cancer cell-lines (MDA-MB231 cells, MCF10ACA1, 4T1) the more E gene-expressing cells are associated with CSC-properties. Thus, the identity of CSCs appears to be context-dependent. (B) Our model for CSCs integrates and explains these paradoxes by the existence of stem-like intermediate hybrid E/M cells independent of the tumor cell line. We propose that compared to more ‘polarized’ differentiated E (capable of plasticity) and M cell-types (capable of self-renewal), undifferentiated hybrid E/M cells can generate more mammospheres and hetero...
According to the sequential metastasis model, aggressive mesenchymal (M) metastasis-initiating cells...
Tumors are often heterogeneous in nature and consist of multiple cell types with different phenotypi...
As a field we have made tremendous strides in treating breast cancer, with a decline in the past 30 ...
Breast cancer stem cells (CSCs) are thought to drive recurrence and metastasis. Their identity has b...
Breast cancer stem cells (CSCs) are thought to drive recurrence and metastasis. Their identity has b...
Targeting breast cancer stem cells promises to eliminate the root of metastasis and recurrence and t...
Carcinoma cells residing in an intermediate phenotypic state along the epithelial–mesenchymal (E–M) ...
Breast cancer stem cells (CSCs) are thought to drive recurrence and metastasis. Their iden-tity has ...
The cancer stem cell theory poses that cancers develop from a subset of malignant cells that possess...
BACKGROUND: In analogy to normal stem cell differentiation, the current cancer stem cell (CSC) model...
In analogy to normal stem cell differentiation, the current cancer stem cell (CSC) model presumes a ...
International audienceIn cancer stem cell (CSC) hypothesis, tumors are organized in a hierarchical m...
The cancer stem cell theory poses that cancers\ud develop from a subset of malignant cells that poss...
According to the sequential metastasis model, aggressive mesenchymal (M) metastasis-initiating cells...
Current models of stem cell biology assume that normal and neoplastic stem cells reside at the apice...
According to the sequential metastasis model, aggressive mesenchymal (M) metastasis-initiating cells...
Tumors are often heterogeneous in nature and consist of multiple cell types with different phenotypi...
As a field we have made tremendous strides in treating breast cancer, with a decline in the past 30 ...
Breast cancer stem cells (CSCs) are thought to drive recurrence and metastasis. Their identity has b...
Breast cancer stem cells (CSCs) are thought to drive recurrence and metastasis. Their identity has b...
Targeting breast cancer stem cells promises to eliminate the root of metastasis and recurrence and t...
Carcinoma cells residing in an intermediate phenotypic state along the epithelial–mesenchymal (E–M) ...
Breast cancer stem cells (CSCs) are thought to drive recurrence and metastasis. Their iden-tity has ...
The cancer stem cell theory poses that cancers develop from a subset of malignant cells that possess...
BACKGROUND: In analogy to normal stem cell differentiation, the current cancer stem cell (CSC) model...
In analogy to normal stem cell differentiation, the current cancer stem cell (CSC) model presumes a ...
International audienceIn cancer stem cell (CSC) hypothesis, tumors are organized in a hierarchical m...
The cancer stem cell theory poses that cancers\ud develop from a subset of malignant cells that poss...
According to the sequential metastasis model, aggressive mesenchymal (M) metastasis-initiating cells...
Current models of stem cell biology assume that normal and neoplastic stem cells reside at the apice...
According to the sequential metastasis model, aggressive mesenchymal (M) metastasis-initiating cells...
Tumors are often heterogeneous in nature and consist of multiple cell types with different phenotypi...
As a field we have made tremendous strides in treating breast cancer, with a decline in the past 30 ...